Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy-Reference-Cited by-同舟云学术

Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy

Published:2007-02-01 Issue:4 Volume:21 Page:754-763
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pike-Overzet K,de Ridder D,Weerkamp F,Baert M R M,Verstegen M M A,Brugman M H,Howe S J,Reinders M J T,Thrasher A J,Wagemaker G,van Dongen J J M,Staal F J T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404563.pdf

Reference42 articles.

1. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gamma retroviral vector. Lancet 2004; 364: 2181–2187.

2. Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M . Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002; 76: 295–298.

3. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185–1193.

4. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410–2413.

5. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis;Clinical Proteomics;2024-05-22

2. Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia;HemaSphere;2024-03

3. A dissected LMO2 functional analysis and clinical relevance in brain gliomas;Biochemistry and Biophysics Reports;2023-03

4. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation;Oncogene;2022-07-18

5. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease;Frontiers in Immunology;2020-11-27